Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 study

In the phase 3 LYM-3002 study comparing intravenous VR-CAP with R-CHOP in patients with newly-diagnosed, measurable stage II-IV mantle cell lymphoma, not considered or ineligible for transplant, the median progression-free survival was significantly improved with VR-CAP (24.7 versus 14.4 months with...

Descripción completa

Detalles Bibliográficos
Autores principales: Verhoef, Gregor, Robak, Tadeusz, Huang, Huiqiang, Pylypenko, Halyna, Siritanaratkul, Noppadol, Pereira, Juliana, Drach, Johannes, Mayer, Jiri, Okamoto, Rumiko, Pei, Lixia, Rooney, Brendan, Cakana, Andrew, van de Velde, Helgi, Cavalli, Franco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2017
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5477608/
https://www.ncbi.nlm.nih.gov/pubmed/28183846
http://dx.doi.org/10.3324/haematol.2016.152496

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5477608/
https://www.ncbi.nlm.nih.gov/pubmed/28183846
http://dx.doi.org/10.3324/haematol.2016.152496

Ejemplares similares